Last reviewed · How we verify
Ketamine and Midazolam
Ketamine and midazolam together provide dissociative anesthesia and sedation by blocking NMDA receptors and enhancing GABAergic inhibition, respectively.
Ketamine and midazolam together provide dissociative anesthesia and sedation by blocking NMDA receptors and enhancing GABAergic inhibition, respectively. Used for Procedural sedation and analgesia, Induction of general anesthesia, Emergency department sedation.
At a glance
| Generic name | Ketamine and Midazolam |
|---|---|
| Also known as | Ketalar (Ketamin, Pfizer) and Dormicum (Midazolam, Roche), katalar and Dormicum |
| Sponsor | Kanuni Sultan Suleyman Training and Research Hospital |
| Drug class | Dissociative anesthetic and benzodiazepine combination |
| Target | NMDA receptor (ketamine); GABA-A receptor (midazolam) |
| Modality | Small molecule |
| Therapeutic area | Anesthesia and Sedation |
| Phase | FDA-approved |
Mechanism of action
Ketamine is a non-competitive NMDA receptor antagonist that produces dissociative anesthesia while maintaining airway reflexes and spontaneous breathing. Midazolam is a benzodiazepine that enhances GABA-A receptor activity, producing sedation and anxiolysis. This combination is used clinically to achieve rapid sedation and analgesia with preserved hemodynamic stability.
Approved indications
- Procedural sedation and analgesia
- Induction of general anesthesia
- Emergency department sedation
Common side effects
- Dissociation and emergence reactions
- Respiratory depression
- Hypotension
- Tachycardia
- Nausea and vomiting
- Dizziness
Key clinical trials
- Comparison of Two Intravenous Drug Combinations for Ambulatory Oral & Maxillofacial Surgery (PHASE1)
- The Impact of a Shared Decision-Making Intervention on Intraoperative Patient Experience During Elective Cesarean Delivery Under Spinal Anesthesia (NA)
- A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder (PHASE3)
- Ketamine, SGB and Combination Treatment for TBI (PHASE2)
- Prospective IR-led Sedation Feasibility (PHASE1, PHASE2)
- Ketamine for Treatment-Resistant Bipolar Disorder (PHASE2)
- Comparative Assessment of Oral Premedication Regimens in Pediatric Ambulatory Surgery (NA)
- Dexmedetomidine-Midazolam vs. Ketamine-Midazolam on Emergence Delirium (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ketamine and Midazolam CI brief — competitive landscape report
- Ketamine and Midazolam updates RSS · CI watch RSS
- Kanuni Sultan Suleyman Training and Research Hospital portfolio CI